Many stocks performed well last year, but (NYSE: MDT) wasn't one of them. The medical device giant failed to keep pace with broader equities, partly because it was still dealing with lingering pandemic-related issues, such as supply chain problems. However, Medtronic has a long and impressive track record of growing its revenue and earnings at a good clip and delivering solid returns to its shareholders.
While the past isn't a guarantee of anything, it's also important not to write off the company because of the headwinds it encountered in recent years. With that said, let's look deeper into Medtronic's business and decide whether it is worth buying its shares today.
Investors have been unsatisfied with Medtronic's revenue growth since before the pandemic.
Source Fool.com